Larson Financial Group LLC Boosts Holdings in Agilent Technologies, Inc. (NYSE:A)

Larson Financial Group LLC lifted its stake in shares of Agilent Technologies, Inc. (NYSE:A) by 8.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,437 shares of the medical research company’s stock after acquiring an additional 349 shares during the period. Larson Financial Group LLC’s holdings in Agilent Technologies were worth $596,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of the stock. Vestal Point Capital LP purchased a new stake in Agilent Technologies during the third quarter valued at about $14,848,000. Empowered Funds LLC grew its holdings in shares of Agilent Technologies by 29.8% during the 3rd quarter. Empowered Funds LLC now owns 30,978 shares of the medical research company’s stock worth $4,592,000 after purchasing an additional 7,111 shares during the period. S.E.E.D. Planning Group LLC increased its position in Agilent Technologies by 12.7% during the 4th quarter. S.E.E.D. Planning Group LLC now owns 42,587 shares of the medical research company’s stock worth $5,721,000 after purchasing an additional 4,805 shares in the last quarter. Miracle Mile Advisors LLC purchased a new position in Agilent Technologies in the fourth quarter valued at approximately $362,000. Finally, Massachusetts Financial Services Co. MA lifted its position in Agilent Technologies by 3.5% during the third quarter. Massachusetts Financial Services Co. MA now owns 15,589,874 shares of the medical research company’s stock valued at $2,314,784,000 after buying an additional 525,214 shares in the last quarter.

Agilent Technologies Price Performance

Shares of NYSE A opened at $126.59 on Monday. The company has a quick ratio of 1.66, a current ratio of 2.20 and a debt-to-equity ratio of 0.56. Agilent Technologies, Inc. has a fifty-two week low of $121.45 and a fifty-two week high of $155.35. The business has a 50 day moving average price of $139.67 and a two-hundred day moving average price of $138.68. The firm has a market cap of $36.09 billion, a PE ratio of 29.10, a price-to-earnings-growth ratio of 3.56 and a beta of 1.11.

Agilent Technologies (NYSE:A) last released its quarterly earnings results on Wednesday, February 26th. The medical research company reported $1.31 earnings per share for the quarter, topping analysts’ consensus estimates of $1.27 by $0.04. The business had revenue of $1.68 billion during the quarter, compared to the consensus estimate of $1.67 billion. Agilent Technologies had a net margin of 19.27% and a return on equity of 25.56%. Sell-side analysts expect that Agilent Technologies, Inc. will post 5.57 earnings per share for the current fiscal year.

Agilent Technologies Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, April 23rd. Stockholders of record on Tuesday, April 1st will be paid a $0.248 dividend. The ex-dividend date is Tuesday, April 1st. This represents a $0.99 dividend on an annualized basis and a dividend yield of 0.78%. Agilent Technologies’s dividend payout ratio (DPR) is presently 22.76%.

Insider Transactions at Agilent Technologies

In other Agilent Technologies news, CEO Padraig Mcdonnell sold 1,911 shares of Agilent Technologies stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $150.00, for a total value of $286,650.00. Following the completion of the transaction, the chief executive officer now owns 39,652 shares of the company’s stock, valued at $5,947,800. The trade was a 4.60 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the stock. JPMorgan Chase & Co. dropped their price objective on shares of Agilent Technologies from $165.00 to $160.00 and set an “overweight” rating for the company in a research report on Tuesday, November 26th. Citigroup increased their price target on Agilent Technologies to $165.00 and gave the company a “buy” rating in a report on Thursday, December 19th. Sanford C. Bernstein reduced their price objective on Agilent Technologies from $140.00 to $135.00 and set a “market perform” rating on the stock in a research note on Tuesday, November 26th. Robert W. Baird lowered their target price on Agilent Technologies from $161.00 to $159.00 and set an “outperform” rating for the company in a research note on Thursday, February 27th. Finally, StockNews.com upgraded Agilent Technologies from a “hold” rating to a “buy” rating in a report on Tuesday, December 24th. Seven analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat, Agilent Technologies presently has a consensus rating of “Moderate Buy” and an average target price of $146.15.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.